Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1989 3
1990 1
1992 1
1996 1
1998 1
2000 2
2002 1
2004 2
2005 7
2006 4
2007 4
2008 8
2009 4
2010 5
2011 4
2012 3
2013 1
2014 4
2015 2
2016 3
2017 1
2018 5
2019 13
2020 5
2021 7
2022 7
2023 5
2024 12
2025 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

114 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
Ensembles of endothelial and mural cells promote angiogenesis in prenatal human brain.
Crouch EE, Bhaduri A, Andrews MG, Cebrian-Silla A, Diafos LN, Birrueta JO, Wedderburn-Pugh K, Valenzuela EJ, Bennett NK, Eze UC, Sandoval-Espinosa C, Chen J, Mora C, Ross JM, Howard CE, Gonzalez-Granero S, Lozano JF, Vento M, Haeussler M, Paredes MF, Nakamura K, Garcia-Verdugo JM, Alvarez-Buylla A, Kriegstein AR, Huang EJ. Crouch EE, et al. Cell. 2022 Sep 29;185(20):3753-3769.e18. doi: 10.1016/j.cell.2022.09.004. Cell. 2022. PMID: 36179668 Free PMC article.
Vaccine Efficacy in Adults in a Respiratory Syncytial Virus Challenge Study.
Schmoele-Thoma B, Zareba AM, Jiang Q, Maddur MS, Danaf R, Mann A, Eze K, Fok-Seang J, Kabir G, Catchpole A, Scott DA, Gurtman AC, Jansen KU, Gruber WC, Dormitzer PR, Swanson KA. Schmoele-Thoma B, et al. N Engl J Med. 2022 Jun 23;386(25):2377-2386. doi: 10.1056/NEJMoa2116154. N Engl J Med. 2022. PMID: 35731653 Clinical Trial.
Nonglucuronidated Ezetimibe Disrupts CD13- and CD64-Coassembly in Membrane Microdomains and Decreases Cellular Cholesterol Content in Human Monocytes/Macrophages.
Orsó E, Robenek H, Boettcher A, Wolf Z, Liebisch G, Kramer W, Schmitz G. Orsó E, et al. Cytometry A. 2019 Aug;95(8):869-884. doi: 10.1002/cyto.a.23772. Epub 2019 Apr 17. Cytometry A. 2019. PMID: 30994973 Free article.
Cellular effects of EZE, EZE-Glu, and the low-absorbable EZE-analogue S6130 were investigated on human monocyte-derived macrophages upon loading with atherogenic lipoproteins. ...Administration of EZE, but not of EZE-Glu or S6130, was associated …
Cellular effects of EZE, EZE-Glu, and the low-absorbable EZE-analogue S6130 were investigated on human monocyte-derived …
Comparing remnant lipoprotein cholesterol measurement methods to evaluate efficacy of ezetimibe/statin vs statin therapy.
Toth PP, Bays HE, Brown WV, Catapano AL, Davidson MH, Farnier M, Tomassini JE, Jensen E, Polis AB, Tershakovec AM. Toth PP, et al. J Clin Lipidol. 2019 Nov-Dec;13(6):997-1007.e8. doi: 10.1016/j.jacl.2019.09.001. Epub 2019 Sep 11. J Clin Lipidol. 2019. PMID: 31629703
OBJECTIVE: To evaluate the effect of ezetimibe (Eze) + statins vs statin monotherapy on RLP-C using immunoseparation (IM), vertical auto profile (VAP) ultracentrifugation, and calculated RLP-C measurement methods. ...CONCLUSION: Although the 3 methods showed …
OBJECTIVE: To evaluate the effect of ezetimibe (Eze) + statins vs statin monotherapy on RLP-C using immunoseparation (IM), ver …
Differential Adherence to Free and Single-Pill Combination of Rosuvastatin/Ezetimibe: Findings from a Real-World Analysis in Italy.
Perez de Isla L, Liberopoulos E, Dovizio M, Veronesi C, Degli Esposti L, Zambon A. Perez de Isla L, et al. Adv Ther. 2024 Aug;41(8):3407-3418. doi: 10.1007/s12325-024-02916-8. Epub 2024 Jul 4. Adv Ther. 2024. PMID: 38963586 Free PMC article.
This analysis assessed the possible changes in adherence in patients treated with rosuvastatin and ezetimibe (ROS/EZE) as free multi-pill combination who switched to ROS/EZE as single-pill combination in the setting of real clinical practice in Italy. ...The date of …
This analysis assessed the possible changes in adherence in patients treated with rosuvastatin and ezetimibe (ROS/EZE) as free multi- …
Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia.
McKenney JM, Farnier M, Lo KW, Bays HE, Perevozkaya I, Carlson G, Davies MJ, Mitchel YB, Gumbiner B. McKenney JM, et al. J Am Coll Cardiol. 2006 Apr 18;47(8):1584-7. doi: 10.1016/j.jacc.2005.11.072. Epub 2006 Mar 30. J Am Coll Cardiol. 2006. PMID: 16630994 Free article. Clinical Trial.
There were also significantly greater improvements in triglycerides, high-density lipoprotein cholesterol (HDL-C), total cholesterol, non-HDL-C, and apolipoprotein B with FENO plus EZE compared with FENO. Changes in apolipoprotein A-I and high-sensitivity …
There were also significantly greater improvements in triglycerides, high-density lipoprotein cholesterol (HDL-C), total cholesterol, …
APOL1 Bi- and Monoallelic Variants and Chronic Kidney Disease in West Africans.
Gbadegesin RA, Ulasi I, Ajayi S, Raji Y, Olanrewaju T, Osafo C, Ademola AD, Asinobi A, Winkler CA, Burke D, Arogundade F, Ekem I, Plange-Rhule J, Mamven M, Matekole M, Amodu O, Cooper R, Antwi S, Adeyemo AA, Ilori TO, Adabayeri V, Nyarko A, Ghansah A, Amira T, Solarin A, Awobusuyi O, Kimmel PL, Brosius FC, Makusidi M, Odenigbo U, Kretzler M, Hodgin JB, Pollak MR, Boima V, Freedman BI, Palmer ND, Collins B, Phadnis M, Smith J, Agwai CI, Okoye O, Abdu A, Wilson J, Williams W, Salako BL, Parekh RS, Tayo B, Adu D, Ojo A; H3Africa Kidney Disease Research Network. Gbadegesin RA, et al. N Engl J Med. 2025 Jan 16;392(3):228-238. doi: 10.1056/NEJMoa2404211. Epub 2024 Oct 26. N Engl J Med. 2025. PMID: 39465900 Free PMC article.
Efficacy and safety of ezetimibe 40 mg vs. ezetimibe 10 mg in the treatment of patients with homozygous sitosterolaemia.
Musliner T, Cselovszky D, Sirah W, McCrary Sisk C, Sapre A, Salen G, Lütjohann D, von Bergmann K. Musliner T, et al. Int J Clin Pract. 2008 Jul;62(7):995-1000. doi: 10.1111/j.1742-1241.2008.01786.x. Epub 2008 May 14. Int J Clin Pract. 2008. PMID: 18484971 Clinical Trial.
Median per cent changes in the EZE 40 mg/day and EZE 10 mg/day groups, respectively, were 1.3% and 0% for LDL sterols and 2.5% and 4.4% for LDL-C (p = ns for both between-group differences). ...EZE 10 mg/day. EZE 40 mg/day had a safety and toler …
Median per cent changes in the EZE 40 mg/day and EZE 10 mg/day groups, respectively, were 1.3% and 0% for LDL sterols and 2.5% …
114 results